Lineage Cell Therapeutics (LCTX) Receivables - Other (2011 - 2026)

Lineage Cell Therapeutics (LCTX) posted quarterly Receivables - Other of $585000.0 for Q1 2026, down 12.82% quarter-over-quarter from $671000.0 in Q4 2025.

Lineage Cell Therapeutics (LCTX) Receivables - Other (2011 - 2026) Analysis & Trends

Lineage Cell Therapeutics' Receivables - Other history runs 10 years deep, the most recent figure standing at $585000.0 for Q1 2026.

  • In Q1 2026, Receivables - Other changed N/A year-over-year to $585000.0; the TTM figure through Mar 2026 stood at $585000.0 (changed N/A YoY), while the FY2025 annual figure was $671000.0, changed N/A from the prior year.
  • Receivables - Other for Q1 2026 stood at $585000.0, down from $671000.0 in the prior quarter.
  • The five-year high for Receivables - Other was $671000.0 in Q4 2025, with the low at $545000.0 in Q3 2022.
  • The 3-year median for Receivables - Other is $581000.0 (2022), against an average of $586200.0.
  • Peak annual rise in Receivables - Other reached 8.6% in 2022, while the deepest fall reached 8.6% in 2022.
  • Lineage Cell Therapeutics' Receivables - Other stood at $581000.0 in 2022, then gained by 15.49% to $671000.0 in 2025, then retreated by 12.82% to $585000.0 in 2026.
  • Business Quant data shows LCTX's Receivables - Other at $585000.0 in Q1 2026, $671000.0 in Q4 2025, and $549000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Lineage Cell Therapeutics 270.61 Mn 212.77 Mn 1.07 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 166,000.00
Jun 30, 2026 166,000.00
Mar 31, 2026 585,000.00
Mar 31, 2026 585,000.00
Dec 31, 2025 671,000.00
Dec 31, 2025 671,000.00
Sep 30, 2025 549,000.00
Sep 30, 2025 549,000.00
Dec 31, 2022 581,000.00
Dec 31, 2022 581,000.00
Sep 30, 2022 545,000.00
Sep 30, 2022 545,000.00
Dec 31, 2021 535,000.00
Dec 31, 2021 535,000.00
Jun 30, 2020 7,000.00
Jun 30, 2020 7,000.00
Mar 31, 2020 47,000.00
Mar 31, 2020 47,000.00
Dec 31, 2019 7,000.00
Dec 31, 2019 7,000.00